T-Cell Lymphoma Treatment Market By Type (Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Cutaneous T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma, Others), By Drugs (Chemotherapy Drugs, Corticosteroids, Immunomodulators, Targeted Therapy Drugs, Gene Therapy Drugs) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Industry Outlook

T-cell lymphoma treatment market accounted for a market value of US$ 862.1 Mn in 2017 and projected to grow at a CAGR of 11.7% during the forecast period from 2018 to 2026. Lymphoma is divided into two types Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma. Non-Hodgkin’s lymphoma is segmented as B-cell lymphoma and T-cell lymphoma, B-cell lymphoma accounted nearly 85% of the lymphoma diagnoses and remaining 15% being T-cell lymphoma. T-cell lymphoma is considered as the most complex lymphoma which makes it very difficult to diagnose. However, developing diagnostic technologies and incessant research and development in the field of T-cell lymphoma treatment is expected to assist the growth of this market throughout the forecast period. On 16th November 2018, FDA approved first-line treatment for peripheral T-cell lymphoma named Adcertis (brentuximab vedotin) in combination with chemotherapy for adult patients with specific types of peripheral T-cell lymphoma (PTCL). Brentuximab vedotin is a monoclonal antibody that binds to a protein (called CD30) identified on some cancer cells. Thus, such novel drug therapies entering in the T-cell lymphoma treatment market expected to drive the overall growth of the market throughout the forecast period from 2018 to 2026.

Market Synopsis

Get a sample copy for more information

"Cutaneous T-cell lymphoma is the largest and peripheral T-cell lymphoma expected to be the fastest growing T-cell lymphoma treatment market"

According to Premera Blue Cross, the projected annual incidence of CTCL is 0.4 to 1 case per 100,000 (or 1,000 to 3,000 new cases per year) in the United States. However, mortality rate of CTCL is not high and patients can live with CTCL around 10 or more. The average estimated prevalence of CTCL in the U.S. is approximately 20,000. Thus, this makes CTCL most prevalent type of t-cell lymphoma providing it overall market share of 32% in T-cell lymphoma treatment market for year 2017. However, promising pipeline and recent drug approvals such as Adcertis makes PTCL one of the fastest growing T-cell lymphoma type market throughout the forecast period from 2018 to 2026.

Get a sample copy for more information

"North America identified as the largest and fastest growing T-cell lymphoma treatment market due to introduction of novel therapies & high prevalence rate of T-cell lymphoma"

North America will maintain its dominance throughout the forecast period in T-cell lymphoma treatment market due to key driving factors such as rising prevalence & awareness related to T-cell lymphoma, promising drug pipeline & upcoming drug launches, and increasing demand for target-specific & safe drugs. According to cutaneous lymphoma foundation, CTCL is a rare disease with around 3,000 new cases recorded in the United States each year. CTCL found usually in men compared to women and specifically in patients aged above 50 years.

Get a sample copy for more information

Historical & Forecast Period 

The T-cell lymphoma treatment market analyzed considering current market trends for base year 2017 and based on future trends CAGRs calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

This report covers in-depth analysis of T-cell lymphoma treatment market covering quantitative and qualitative information along with the key market drivers, opportunities & restraints that affect or assist the overall global market. The market drivers, challenges & opportunities also covered exclusively for country-level market in the corresponding segments. This report covers in-depth information associated with global T-cell lymphoma treatment market with segments such as types of T-cell lymphoma, drugs, and geography. Report comprises competitive analysis of the key players functioning in T-cell lymphoma treatment market that covers in-depth data related to competitive landscape of the market and the recent strategies & product pipeline affecting the market in the near future.

The key players present in the market analyzed based on product portfolio, financial information, recent market updates, and key market strategies. This report also comprises attractive investment proposition analyzed with the help of exhaustive geographical research based on PESTEL analysis. Key players profiled in the report include Actelion Pharmaceuticals, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Celgene Corporation, Seattle Genetics, Shenzen ChipScreen Biosciences, Ltd., Genmab A/S, Medivir AB, Amgen, Inc., Eisai, Inc., F. Hoffman La-Roche, and Sorrento Therapeutics, Inc., among others.

Key questions answered in this report

• Which is the trending drug type in the market preferred against T-cell lymphoma & Why?
• What are the current market strategies followed by key players & competitive analysis specific to T-cell lymphoma treatment market?
• Which are the key geographical markets (regions and countries) in T-cell lymphoma treatment market?
• Which is the largest and fastest growing T-cell lymphoma types globally?
• How is the competition in T-cell lymphoma treatment market and strategies of key players functioning in this industry?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global T-CLT Market Portraiture
2.2. Global T-CLT Market, by Type of T-Cell Lymphoma, 2017 (US$ Mn)
2.3. Global T-CLT Market, by Drugs, 2017 (US$ Mn
2.4. Global T-CLT Market, by Geography, 2017 Vs 2026 (Value %)

Chapter 3. Global T-Cell Lymphoma Treatment (T-CLT) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.2.1. High awareness of T-cell lymphoma in medical practitioners and patients
3.2.2. Rising prevalence of T-cell lymphoma due to developed diagnostic technologies
3.3. Challenges
3.3.1. Novel drug therapies entering in the market are high priced
3.4. Opportunities
3.4.1. Strong and deep product pipeline will provide significant growth to the overall market in the near future
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2017

Chapter 4. Global T-Cell Lymphoma Treatment (T-CLT) Market, by Type of T-cell Lymphoma, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Peripheral T-Cell Lymphoma
4.3. Anaplastic Large Cell Lymphoma
4.4. Angioimmunoblastic T-Cell Lymphoma
4.5. Cutaneous T-Cell Lymphoma
4.6. Adult T-Cell Leukemia/Lymphoma
4.7. Others (Lymphoblastic lymphoma, Enteropathy-associated intestinal T-cell lymphoma, and Extranodal T-cell lymphoma)

Chapter 5. Global T-Cell Lymphoma Treatment (T-CLT) Market, by Drugs, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. Chemotherapy Drugs
5.2.1. Cyclophosphamide
5.2.2. Doxorubicin
5.2.3. Vincristine
5.2.4. Etoposide
5.2.5. Gemcitabine
5.2.6. Pralatrexate
5.2.7. Navelbine
5.2.8. Others (Oxaliplatin, Gemcitabine, Cholormethine, Methotrexate & Mechlorethamine)
5.3. Corticosteroids
5.3.1. Prednisone
5.3.2. Dexamethasone
5.4. Immunomodulators
5.4.1. Lenalodimide
5.4.2. Interferon alfa-2b
5.4.3. Cyclosporine
5.4.4. Imiquimod
5.4.5. Bexarotene
5.4.6. Tazarotene
5.4.7. Forodesine (Mundesine)
5.5. Targeted Therapy Drugs
5.5.1. Alemtuzumab
5.5.2. Belinostat
5.5.3. Brentuximab vedotin
5.5.4. Romidespin
5.5.5. Rituximab
5.5.6. Mogamulizumab
5.5.7. Nivolumab
5.6. Gene Therapy Drugs
5.6.1. Yescarta (axicabtagene ciloleucel)
5.6.2. Kymirah (tisagenlecleucel)

Chapter 6. Global T-Cell Lymphoma Treatment (T-CLT) Market: Pipeline Analysis
6.1. Overview
6.2. Phase III (Forecast Till 2026)
6.2.1. SGX301 (Soligenix, Inc.)
6.2.2. Remetinostat (Medivir AB)
6.2.3. Chidamide (Shenzhen Chipscreen Biosciences, Ltd.)
6.2.4. Romidespin (Celgene Corporation)
6.3. Phase II (Tabular Information)
6.3.1. Tipifarnib (Kura Oncology, Inc.)
6.3.2. SP-02 (ZIOPHARM Oncology, Inc.)
6.3.3. ALRN-6924 (Aleron Therapeutics)
6.3.4. AUTO4 (Autolus Therapeutics plc)
6.3.5. E7777 (Eisai, Inc.)
6.3.6. Daratumumab (Genmab A/S)
6.3.7. CD11301 (Galderma S.A.)
6.3.8. NM-IL-12 (Neumedicines Inc.)
6.4. Phase I (Tabular Representation)
6.4.1. IPH4102 (Innate Pharma)
6.4.2. MRG – 106 (miRagen Therapeutics, Inc.)
6.4.3. TTI-621 (Trillium Therapeutics Inc.)
6.4.4. Belinostat (Beleodaq®) (Spectrum Pharmaceuticals, Inc. )

Chapter 7. Global T-Cell Lymphoma Treatment (T-CLT) Market, by Geography, 2016 – 2026 (US$ Mn)
7.1. Overview
7.2. North America T-CLT Market Analysis, 2016 – 2026
7.2.1. North America T-CLT Market, by Type of T-Cell Lymphoma, 2016–2026 (US$ Mn)
7.2.2. North America T-CLT Market, by Drugs, 2016–2026 (US$ Mn)
7.2.3. North America T-CLT Market, by Country, 2016 – 2026 (US$ Mn)
7.2.3.1. U.S.
7.2.3.2. Canada
7.3. Europe T-CLT Market Analysis, 2016 – 2026
7.3.1. Europe T-CLT Market, by Type of T-Cell Lymphoma, 2016–2026 (US$ Mn)
7.3.2. Europe T-CLT Market, by Drugs, 2016–2026 (US$ Mn)
7.3.3. Europe T-CLT Market, by Country, 2016 – 2026 (US$ Mn)
7.3.3.1. U.K.
7.3.3.2. Germany
7.3.3.3. Rest of Europe
7.4. Asia Pacific T-CLT Market Analysis, 2016 – 2026
7.4.1. Asia Pacific T-CLT Market, by Type of T-Cell Lymphoma, 2016–2026 (US$ Mn)
7.4.2. Asia Pacific T-CLT Market, by Drugs, 2016–2026 (US$ Mn)
7.4.3. Asia Pacific T-CLT Market, by Country, 2016 – 2026 (US$ Mn)
7.4.3.1. Japan
7.4.3.2. China
7.4.3.3. Rest of APAC
7.5. Latin America T-CLT Market Analysis, 2016 – 2026
7.5.1. Latin America T-CLT Market, by Type of T-Cell Lymphoma, 2016–2026 (US$ Mn)
7.5.2. Latin America T-CLT Market, by Drugs, 2016–2026 (US$ Mn)
7.5.3. Latin America T-CLT Market, by Country, 2016 – 2026 (US$ Mn)
7.5.3.1. Brazil
7.5.3.2. Mexico
7.5.3.3. Rest of Latin America
7.6. Middle East & Africa (MEA) T-CLT Market Analysis, 2016 – 2026
7.6.1. Middle East & Africa T-CLT Market, by Type of T-Cell Lymphoma, 2016–2026 (US$ Mn)
7.6.2. Middle East & Africa T-CLT Market, by Drugs, 2016–2026 (US$ Mn)
7.6.3. MEA T-CLT Market, by Region, 2016 – 2026 (US$ Mn)
7.6.3.1. GCC
7.6.3.2. Rest of MEA

Chapter 8. Company Profiles
8.1. Actelion Pharmaceuticals
8.1.1. Business Description
8.1.2. Financial Information (Subject to data availability)
8.1.3. Product Portfolio
8.1.4. Key Developments
8.2. Spectrum Pharmaceuticals
8.3. Bristol-Myers Squibb
8.4. Shenzen ChipScreen Biosciences, Ltd.
8.5. Celgene Corporation
8.6. Eisai, Inc.
8.7. Genmab A/S
8.8. Galderma S.A.
8.9. Kyowa Hakko Kirin Co., Ltd.
8.10. Novartis AG
8.11. Neumedicines, Inc.
8.12. Amgen, Inc.
8.13. F. Hoffman La-Roche
8.14. Seattle Genetics
8.15. Soligenix, Inc.
8.16. ZIOPHARM Oncology
8.17. Medivir AB
8.18. Kura Oncology, Inc.
8.19. Aleron Therapeutics
8.20. Autolus Therapeutics plc
8.21. Innate Pharma
8.22. miRagen Therapeutics, Inc.
8.23. Trillium Therapeutics Inc.
8.24. Bellicum Pharmaceuticals, Inc.
8.25. Sorrento Therapeutics, Inc.

* T-CLT - T-Cell Lymphoma Treatment

FIG. 1 T-Cell Lymphoma Treatment (T-CLT) Market Segmentation
FIG. 2 Global T-CLT Market Share, by Type of T-Cell Lymphoma, 2017 (US$ Mn)
FIG. 3 Global T-CLT Market Share, by Drug, 2017 (US$ Mn)
FIG. 4 Global T-CLT Market, by Geography, 2017 Vs 2026 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography, 2017
FIG. 6 Market Competition Landscape, by Key Players, 2017
FIG. 7 Global Peripheral T-CLT Market, 2016 – 2026 (US$ Mn)
FIG. 8 Global Anaplastic Large Cell Lymphoma Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 9 Global Angioimmunoblastic T-Cell Lymphoma Market, 2016 – 2026 (US$ Mn)
FIG. 10 Global Cutaneous T-Cell Lymphoma Market, 2016 – 2026 (US$ Mn)
FIG. 11 Global Adult T-Cell Leukemia/Lymphoma Market, 2016 – 2026 (US$ Mn)
FIG. 12 Global Other Lymphoma Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 13 Global Cyclophosphamide Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 14 Global Doxorubicin Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 15 Global Vincristine Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 16 Global Etoposide Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 17 Global Gemcitabine Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 18 Global Pralatrexate Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 19 Global Navelbine Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 20 Global Other Chemotherapy Drugs Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 21 Global Prednisone Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 22 Global Dexamethasone Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 23 Global Lenalodimide Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 24 Global Interferon alfa-2b Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 25 Global Cyclosporine Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 26 Global Imiquimod Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 27 Global Bexarotene Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 28 Global Tazarotene Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 29 Global Forodesine (Mundesine) Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 30 Global Alemtuzumab Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 31 Global Belinostat Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 32 Global Brentuximab vedotin Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 33 Global Romidespin Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 34 Global Rituximab Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 35 Global Mogamulizumab Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 36 Global Nivolumab Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 37 Global Yescarta Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 38 Global Kymirah Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 39 Global SGX301 Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 40 Global Remetinostat Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 41 Global Chidamide Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 42 Global Romidespin Market for T-CLT, 2016 – 2026 (US$ Mn)
FIG. 43 U.S. T-CLT Market, 2016 – 2026 (US$ Mn)
FIG. 44 Canada T-CLT Market, 2016 – 2026 (US$ Mn)
FIG. 45 U.K. T-CLT Market, 2016 – 2026 (US$ Mn)
FIG. 46 Germany T-CLT Market, 2016 – 2026 (US$ Mn)
FIG. 47 Rest Of Europe T-CLT Market, 2016 – 2026 (US$ Mn)
FIG. 48 Japan T-CLT Market, 2016 – 2026 (US$ Mn)
FIG. 49 China T-CLT Market, 2016 – 2026 (US$ Mn)
FIG. 50 Rest Of Asia Pacific T-CLT Market, 2016 – 2026 (US$ Mn)
FIG. 51 Brazil T-CLT Market, 2016 – 2026 (US$ Mn)
FIG. 52 Mexico T-CLT Market, 2016 – 2026 (US$ Mn)
FIG. 53 Rest Of Latin America T-CLT Market, 2016 – 2026 (US$ Mn)
FIG. 54 GCC T-CLT Market, 2016 – 2026 (US$ Mn)
FIG. 55 Rest Of Middle East And Africa T-CLT Market, 2016 – 2026 (US$ Mn)

TABLE 1 Global T-CLT (T-CLT) Market, by Type of T-Cell Lymphoma, 2016 – 2026 (US$ Mn)
TABLE 2 Global T-CLT Market, by Drugs, 2016 – 2026 (US$ Mn)
TABLE 3 Global Chemotherapy Drugs Market for T-CLT, by Type, 2016 – 2026 (US$ Mn)
TABLE 4 Global Corticosteroids Market for T-CLT, by Type, 2016 – 2026 (US$ Mn)
TABLE 5 Global Immunomodulators Market for T-CLT, by Type, 2016 – 2026 (US$ Mn)
TABLE 6 Global Targeted Therapy Drugs Market for T-CLT, by Type, 2016 – 2026 (US$ Mn)
TABLE 7 Global Gene Therapy Drugs Market for T-CLT, by Type, 2016 – 2026 (US$ Mn)
TABLE 8 Phase III Drugs for Treatment of T-Cell Lymphoma, Forecast Till 2026 (US$ Mn)
TABLE 9 North America T-CLT Market, by Type of T-Cell Lymphoma, 2016 – 2026 (US$ Mn)
TABLE 10 North America T-CLT Market, by Drugs, 2016 – 2026 (US$ Mn)
TABLE 11 North America T-CLT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Europe T-CLT Market, by Type of T-Cell Lymphoma, 2016 – 2026 (US$ Mn)
TABLE 13 Europe T-CLT Market, by Drugs, 2016 – 2026 (US$ Mn)
TABLE 14 Europe T-CLT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 15 Asia Pacific T-CLT Market, by Type of T-Cell Lymphoma, 2016 – 2026 (US$ Mn)
TABLE 16 Asia Pacific T-CLT Market, by Drugs, 2016 – 2026 (US$ Mn)
TABLE 17 Asia Pacific T-CLT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 18 Latin America T-CLT Market, by Type of T-Cell Lymphoma, 2016 – 2026 (US$ Mn)
TABLE 19 Latin America T-CLT Market, by Drugs, 2016 – 2026 (US$ Mn)
TABLE 20 Latin America T-CLT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 21 Middle East & Africa T-CLT Market, by Type of T-Cell Lymphoma, 2016 – 2026 (US$ Mn)
TABLE 22 Middle East & Africa T-CLT Market, by Drugs, 2016 – 2026 (US$ Mn)
TABLE 23 Middle East And Africa T-CLT Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 24 Actelion Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Spectrum Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 Bristol-Myers Squibb: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 27 Shenzen ChipScreen Biosciences, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 28 Celgene Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 29 Eisai, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 30 Genmab A/S: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 31 Galderma S.A.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 32 Kyowa Hakko Kirin Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 33 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 34 Neumedicines, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 35 Amgen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 36 F. Hoffman La-Roche: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 37 Seattle Genetics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 38 Soligenix, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 39 ZIOPHARM Oncology: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 40 Medivir AB: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 41 Kura Oncology, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 42 Aleron Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 43 Autolus Therapeutics plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 44 Innate Pharma: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 45 miRagen Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 46 Trillium Therapeutics Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 47 Bellicum Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 48 Sorrento Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)